Results 211 to 220 of about 147,468 (308)

A Systematic Review and Meta‐Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition

open access: yesObesity Reviews, EarlyView.
ABSTRACT Background In 2023 and 2024, research into semaglutide (SEMA), an antiobesity and antidiabetic medication, indicated potential benefits beyond its approved uses, particularly in preventing Alzheimer's disease (AD). This highlights the link between obesity and AD development.
Amene Saghazadeh   +14 more
wiley   +1 more source

Canonical and non‐canonical functions of proteins regulating mitochondrial dynamics in mammalian physiology

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Mitochondria are highly dynamic organelles that continuously remodel their architecture through coordinated cycles of fusion and fission. This review examines the four key GTPases that orchestrate mitochondrial dynamics in mammals: MFN1, MFN2, OPA1, and DRP1.
Rémi Chaney   +4 more
wiley   +1 more source

Prediabetic cardiomyopathy is attenuated by hypothalamic PVN oxytocin neuron activation

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend A long‐term high‐fat, high‐fructose diet induces prediabetes with insulin resistance, hyperinsulinaemia, elevated triglycerides and metabolic‐associated steatotic liver disease (MASLD) in male rats. Animals developed prediabetic cardiomyopathy characterized by diastolic dysfunction, interstitial fibrosis and tachycardia ...
Anna Nilsson   +7 more
wiley   +1 more source

Equol Alleviates Postmenopausal Metabolic Dysfunction‐Associated Steatotic Liver Disease via the GPR30/PI3K Pathway

open access: yeseFood, Volume 7, Issue 3, June 2026.
This study demonstrates that equol exerts a protective effect on metabolic dysfunction‐associated steatotic liver disease in both in vivo and in vitro by activating the GPR30/PI3K/Nrf2 signaling pathway. Equol's interaction with GPR30 and its ability to activate the PI3K/Nrf2 pathway provide a promising therapeutic strategy for treating metabolic ...
Hanqiang Cui   +8 more
wiley   +1 more source

Systemic Drivers and Molecular Mechanisms of Sarcopenia in Aetiology‐Specific End‐Stage Liver Disease

open access: yesJournal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 3, June 2026.
ABSTRACT Background Patients with end‐stage liver disease (ESLD) often present with sarcopenia, defined as loss of skeletal muscle mass and quality, which is associated with reduced quality of life and increased mortality. However, the molecular mechanisms driving sarcopenia in ESLD are not fully understood and there are currently no therapeutic ...
Thomas Nicholson   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy